/Moderna%20Inc%20HQ-by%20hapabapa%20via%20iStock.jpg)
As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.
Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.
Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting...
The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025.
Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Potbelly Corporation PBPB: This franchise company has seen the Zacks Consensus Estimate for its current year earnings increasing...
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.
Message volume on Stocktwits has surged by over 1,200% since the beginning of the year, reflecting growing interest.
While vaccine-related investments have broadly suffered following Trump’s electoral victory, NVAX stock may represent a compelling compromise.
The U.S. government has been preparing for potential outbreaks, awarding $306 million last week for avian flu preparedness.
This milestone marks the first achievement since the partnership began in May, with the potential for Novavax to earn up to $300 million in additional milestones.
Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health...
The sale is expected to reduce Novavax’s annual operating costs by $80 million.
The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.
Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...
U.S. stocks fell to their worst loss since Election Day as the boost that Wall Street got from last week’s victory for Donald Trump and a cut to interest rates by the Federal Reserve kept fading
The S&P 500 Index ($SPX ) (SPY ) today is down -1.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.03%. Stocks today extended Thursday’s...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.36%. Stocks today are adding to...
December S&P 500 E-Mini futures (ESZ24) are trending down -0.19% this morning as investors held back from making big bets ahead of a crucial U.S. inflation report that could influence the Federal Reserve’s...
Novavax CEO John Jacobs said the biopharma is looking to expand beyond COVID-19 and influenza.
Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.
Knowing these will help you avoid making suboptimal investing decisions.
Let's look beyond this piece of bad news from regulators.
Novavax stock fell 20% in one trading session on the news.
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...
The biotech continues to earn important wins, but is it enough?
Regulators recently approved an updated COVID shot from Novavax.
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END